Risk factors associated with kanamycin-resistant tuberculosis in a Beijing tuberculosis referral hospital

Journal of Medical Microbiology

Volumn 61, Issue PART7, 2012, Pages 960-967

  Yu, Hao Tian ^a,b   Wang, Qi ^a   Yang, Nan ^b   Li, Hong Min ^b   Liang, Jian Qin ^b   Liu, Cui Hua ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b 309TH HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; CHINA; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; URBAN AREA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HOSPITALS; HUMANS; KANAMYCIN; KANAMYCIN RESISTANCE; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84862657187     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.042655-0     Document Type: Article

References (31)

1. Abubakar, I., Moore, J., Drobniewski, F., Kruijshaar, M., Brown, T., Yates, M., Anderson, C., Smith, E. G., Magee, J. & other authors (2009). Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax 64, 512-515.
2. CDC (2006). Notice to readers: revised definition of extensively drugresistant tuberculosis. MMWR Morb Mortal Wkly Rep 55, 1176.
3. Chan, E. D. & Iseman, M. D. (2008). Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 21, 587-595.
4. Chiang, C. Y., Centis, R. & Migliori, G. B. (2010). Drug-resistant tuberculosis: past, present, future. Respirology 15, 413-432.
5. China Tuberculosis Control Collaboration (2004). The effect of tuberculosis control in China. Lancet 364, 417-422.
6. Crofton, J., Chaulet, P. & Maher, D. (1997). Guidelines for the Management of Drug-Resistant Tuberculosis, Rev 1. WHO/TB/96.210. Geneva: World Health Organization.
7. Dye, C., Espinal, M. A., Watt, C. J., Mbiaga, C. & Williams, B. G. (2002). Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 185, 1197-1202.
8. Eisenach, K. D., Cave, M. D., Bates, J. H. & Crawford, J. T. (1990). Polymerase chain reaction amplification of a repetitive DNA sequence specific for Mycobacterium tuberculosis. J Infect Dis 161, 977-981.
9. Espinal, M. A., Laszlo, A., Simonsen, L., Boulahbal, F., Kim, S. J., Reniero, A., Hoffner, S., Rieder, H. L., Binkin, N. & other authors (2001). Global trends in resistance to antituberculosis drugs. N Engl J Med 344, 1294-1303.
10. Huang, T. S., Kunin, C. M., Shin-Jung Lee, S., Chen, Y. S., Tu, H. Z. & Liu, Y. C. (2005). Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 56, 1058-1062.
11. Huong, N. T., Lan, N. T., Cobelens, F. G., Duong, B. D., Co, N. V., Bosman, M. C., Kim, S. J., van Soolingen, D. & Borgdorff, M. W. (2006). Antituberculosis drug resistance in the south of Vietnam: prevalence and trends. J Infect Dis 194, 1226-1232.
12. Kliiman, K. & Altraja, A. (2009). Predictors of extensively drugresistant pulmonary tuberculosis. Ann Intern Med 150, 766-775.
13. Liu, C. H., Li, L., Chen, Z., Wang, Q., Hu, Y. L., Zhu, B. & Woo, P. C. (2011a). Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS ONE 6, e19399.
14. Liu, C. H., Yang, N., Wang, Q., Hu, Y. L., Li, L., Zhang, G. Y. & Zhu, B. (2011b). Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital. Respirology 16, 918-925.
15. Migliori, G. B., Lange, C., Centis, R., Sotgiu, G., Mütterlein, R., Hoffmann, H., Kliiman, K., De Iaco, G., Lauria, F. N. & other authors (2008). Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 31, 1155-1159.
16. Paramasivan, C. N., Rehman, F., Wares, F., Sundar Mohan, N., Sundar, S., Devi, S. & Narayanan, P. R. (2010). First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis 14, 243-246.
17. Prammananan, T., Arjratanakool, W., Chaiprasert, A., Tingtoy, N., Leechawengwong, M., Asawapokee, N., Leelarasamee, A. & Dhiraputra, C. (2005). Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 9, 216-219.
18. Shah, N. S., Pratt, R., Armstrong, L., Robison, V., Castro, K. G. & Cegielski, J. P. (2008). Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 300, 2153-2160.
19. Suárez-García, I., Rodríguez-Blanco, A., Vidal-Pérez, J. L., García-Viejo, M. A., Jaras-Hernández, M. J., López, O. & Noguerado-Asensio, A. (2009). Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis 28, 325-330.
20. Vashakidze, L., Salakaia, A., Shubladze, N., Cynamon, M., Barbakadze, K., Kikvidze, M., Papitashvili, L., Nonikashvili, M., Solomonia, N. & other authors (2009). Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia. Int J Tuberc Lung Dis 13, 1148-1153.
21. Via, L. E., Cho, S. N., Hwang, S., Bang, H., Park, S. K., Kang, H. S., Jeon, D., Min, S. Y., Oh, T. & other authors (2010). Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean patients with drug-resistant tuberculosis. J Clin Microbiol 48, 402-411.
22. Wang, L., Liu, J. & Chin, D. P. (2007). Progress in tuberculosis control and the evolving public-health system in China. Lancet 369, 691-696.
23. Wang, D., Yang, C., Kuang, T., Lei, H., Meng, X., Tong, A., He, J., Jiang, Y., Guo, F. & Dong, M. (2010). Prevalence of multidrug and extensively drug-resistant tuberculosis in Beijing, China: a hospitalbased retrospective study. Jpn J Infect Dis 63, 368-371.
24. WHO (2000). Anti-tuberculosis Drug Resistance in the World. Report no. 2: Prevalence and Trends. The WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance. WHO/CDS/TB/2000.278. Geneva, Switzerland: World Health Organization. Available at: http://whqlibdoc.who.int/hq/2000/WHO_CDS_TB_2000.278_intro.pdf.
25. WHO (2003). Treatment of Tuberculosis: Guidelines for National Programmes, 3rd edn. WHO/CDS/TB/2003.313. Geneva, Switzerland: World Health Organization. Available at: http://whqlibdoc.who.int/hq/2003/who_cds_tb_2003.313_eng.pdf.
26. WHO (2006). Guidelines for the Programmatic Management of Drugresistant Tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: World Health Organization. Available at: http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf.
27. WHO (2010a). Global Tuberculosis Control. WHO Report 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: World Health Organization. Available at: http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf.
28. WHO (2010b). Multidrug and Extensively Drug-resistant TB (M/XDRTB). 2010 Global Report on Surveillance and Response. WHO/HTM/TB/2010.3. Geneva, Switzerland: World Health Organization. Available at: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf.
29. Xianyi, C., Fengzeng, Z., Hongjin, D., Liya, W., Lixia, W., Xin, D. & Chin, D. P. (2002). The DOTS strategy in China: results and lessons after 10 years. Bull World Health Organ 80, 430-436.
30. Xu, P., Li, X., Zhao, M., Gui, X., DeRiemer, K., Gagneux, S., Mei, J. & Gao, Q. (2009). Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother 53, 3170-3172.
31. Zhao, M., Li, X., Xu, P., Shen, X., Gui, X., Wang, L., Deriemer, K., Mei, J. & Gao, Q. (2009). Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS ONE 4, e4370.